Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 2
Submit an article Journal homepage
413
Views
16
CrossRef citations to date
0
Altmetric
Research Report

Cost–effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer

Hind T Hatoum Hind T Hatoum & Company, 155 N Harbor Drive, 1912, Chicago, IL 60601, USA. [email protected]
,
E David Crawford University of Colorado, Denver, Mail Stop F 710, PO Box 6510, Aurora, CO 80045, USA
,
Sandy Kildegaard Nielsen Ferring International Center SA, Chemin de la Vergognausaz 50, CH-1162 St. Prex, Switzerland
,
Swu-Jane Lin Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, 833 South Wood St., Chicago, IL 60612, USA
&
Dennis C Marshall Ferring Pharmaceuticals, Inc., 4 Gatehall Drive, Parsippany, NJ 07054, USA
Pages 261-270 | Published online: 09 Jan 2014

References

  • Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 9(Suppl. 1), S3–S8 (2007).
  • Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J. Natl Compr. Canc. Netw. 8(2), 211–223 (2010).
  • Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 75(3), 642–647 (2010).
  • Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59(4), 572–583 (2011).
  • Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a Phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 57(5), 836–842 (2010).
  • Fisher D, Brereton NJ, Nielsen SK, Tate E. A cost utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in Scotland. Presented at: ISPOR 14th Annual European Congress. Madrid, Spain, 5–8 November 2011.
  • Lu L, Peters J, Roome C, Stein K. Cost–effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 109(8), 1183–1192 (2012).
  • Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group Phase III study in patients with prostate cancer. BJU Int. 102(11), 1531–1538 (2008).
  • Crawford ED, Tombal B, Miller K et al. A Phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 186(3), 889–897 (2011).
  • Gittelman M, Brown TM, Holm-Larsen T, Persson B. Comparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: results of a 12-month Phase III clinical trial. Uro Today Int. J. 4(6), Abstract 81 (2011).
  • Heidenreich A, Bellmunt J, Bolla M et al.; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59(1), 61–71 (2011).
  • Arias E. United States life tables, 2007. Natl Vital Stat. Rep. 59(9), 1–60 (2011).
  • Roberts MS, Sonnenberg FA. Decision modeling techniques. In: Decision Making in Health Care: Theory, Psychology, and Applications. Chapman GB, Sooenberg FA (Eds). Cambridge University Press, Cambridge, UK (2000).
  • Yabroff KR, Lamont EB, Mariotto A et al. Cost of care for elderly cancer patients in the United States. J. Natl Cancer Inst. 100(9), 630–641 (2008).
  • Bayoumi AM, Brown AD, Garber AM. Cost–effectiveness of androgen suppression therapies in advanced prostate cancer. J. Natl Cancer Inst. 92(21), 1731–1739 (2000).
  • Fryback DG, Dunham NC, Palta M et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med. Care 45(12), 1162–1170 (2007).
  • Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost–effectiveness in Health and Medicine: Report of the Panel on Cost–effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
  • Grosse SD. Assessing cost–effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8(2), 165–178 (2008).
  • Ferguson JK, Oesterling JE. Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol. Clin. North Am. 21(4), 677–685 (1994).
  • Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. Urol. Clin. North Am. 21(4), 677–685 (1994).
  • Montie JE. Follow-up after radical prostatectomy or radiation therapy for prostate cancer. Urol. Clin. North Am. 21(4), 673–676 (1994).
  • Scher HI. Management of prostate cancer after prostatectomy: treating the patient, not the PSA. JAMA 281(17), 1642–1645 (1999).
  • Konski A, Watkins-Bruner D; RTOG (Radiation Therapy Oncology Group) Outcomes Model. The RTOG Outcomes Model: economic end points and measures. Expert Opin. Pharmacother. 5(3), 513–519 (2004).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.